Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Dec;44(12):3285-7.
doi: 10.1128/AAC.44.12.3285-3287.2000.

Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis

P R Donald  1 , F A Sirgel, T P Kanyok, L H Danziger, A Venter, F J Botha, D P Parkin, H I Seifart, B W Van De Wal, J S Maritz, D A Mitchison
Affiliations

Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis

P R Donald et al. Antimicrob Agents Chemother. 2000 Dec.

Abstract

The early bactericidal activity of the aminoglycoside paromomycin (aminosidine) in doses of 7.5 and 15 mg/kg of body weight was measured in 22 patients with previously untreated smear-positive pulmonary tuberculosis. The fall in log(10) CFU per milliliter of sputum per day during the first 2 days of treatment for 7 patients receiving a paromomycin dosage of 7.5 mg/kg/day was 0.066, with a standard deviation (SD) of 0.216 and confidence limits from -0.134 to 0.266, and that for 15 patients receiving 15 mg/kg/day was 0.0924, with an SD of 0.140 and confidence limits from 0.015 to 0.170. The difference between the mean and zero was not significant for the 7. 5-mg/kg dose group but was significant for the 15-mg/kg dose group (t = 2.55, P = 0.023). Since paromomycin has no cross-resistance with streptomycin and has no greater toxicity than other aminoglycosides, these results suggest that it has the potential to substitute for streptomycin in antituberculosis regimens and may be a particularly valuable addition to the drug armamentarium for the management of multidrug-resistant tuberculosis.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Plot showing linear regression of EBA of the 7.5- and 15-mg/kg paromomycin groups and the no-drug groups.
See this image and copyright information in PMC

References

    1. Arcamone F, Bertazzoli C, Buogo A, Cassinelli G, Vigevani A. New studies in the field of aminoglycosidic aminocyclitol antibiotics. Panminerva Med. 1974;16:9–24. - PubMed
    1. Chunge C N, Owate J, Pamba H O, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg. 1990;84:221–225. - PubMed
    1. Donald P R, Sirgel F A, Botha F J, Selfart H I, Parkin D P, Van den Plas M, Van de Wal B W, Maritz J S, Mitchison D A. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med. 1997;156:895–900. - PubMed
    1. Eastwood J. Paromomycin: serum levels following parenteral administration. Antibiot Chemother. 1962;12:77–84. - PubMed
    1. Fisher M W, Manning M C, Gagliardi L A, Gaetz M R, Erlandson A L. Paromomycin: experimental antibacterial activity. Antibiot Annu. 1960;7:293–303. - PubMed

Publication types